HPV legislation in Rhode Island

From SourceWatch
Jump to: navigation, search

Women in Government Ratings

Women in Government, a non-profit network of state level women legislators, receives significant funding from the pharmaceutical industry, including Merck, GlaxoSmithKline, and Digene Corporation -- all with products related to HPV vaccination and testing. According to their report, "The 'State' of Cervical Cancer Prevention in America - 2008" [1]:


POPULATION: 1,067,610


Incidence & Mortality (2008 Score / 2007 Score)

  • Cervical Cancer Incidence Rate: 6.8/100,000 (2 / 2)
  • Cervical Cancer Incidence Rate/Race: White: 6.6, Black: 7.6
  • Cervical Cancer Mortality Rate: 2.1/100,000 (1 / 1)
  • Cervical Cancer Mortality Rate/Race: White: 2.1


Screening (2008 Score / 2007 Score)

  • Cervical Cancer Screening Rate: 87.8% (2 / 2)
  • Cervical Cancer Screening Rate/Race: White: 90%, Black: 89.5%, Hispanic: 90.5%
  • % Uninsured/Unscreened: 25.1% (1 / 1)
  • Medicaid Coverage HPV Testing: Unrestricted (2 / 2)


Healthcare Access (2008 Score / 2007 Score)

  • Rate Uninsured Women: 13% (1 / 1)
  • % Low Income/Uninsured Women: 25%


Policy Initiatives and Infrastructure (2008 Score / Cumulative Score (2005–2008)

Screening Requirements (0 / 1)

  • There are no new screening requirements.

Task Forces (0 / 1)

  • There is no new cervical cancer prevention task force legislation.

Access to HPV Vaccines (2 / 2)

  • HB 5061 requires insurance coverage for the HPV vaccine; became law without governor’s signature.

HPV Vaccine Information Programs (0 / 0)

  • There is no HPV vaccine information activity.

Miscellaneous (0 / 2)

  • There is no new miscellaneous cervical cancer prevention activity.


Annual Ratings

  • 2008: Very Good (15 out of 22 points)
  • 2007: Very Good (13 out of 18 points)


Articles and resources

SourceWatch Resources

External links

References

  1. "The 'State' of Cervical Cancer Prevention in America - 2008", Women in Government